全脑放疗联合替莫唑胺治疗非小细胞肺癌脑转移瘤的效果评价

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (36 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the efficacy and side effects of whole brain radiotherapy Combined with Temozolomide in the treatment of brain metastases of non-small cell lung cancer(NSCLC).Methods A total of 56 patients with NSCLC in our hospital from May 2014 to May 2017 were selected as the study objects.According to the random grouping method,all the patients were divided into the study group and the control group,with 28 cases in each group.The study group received whole brain radiotherapy combined with Temozolomide Capsules chemotherapy,whole brain radiotherapy dose was 40 GY/20 F,Temozolomide dose was 75 mg/(m2·d).The control group was treated with simple whole brain radiotherapy,and the dose and method of radiotherapy were the same as those of the study group.The treatment related adverse reactions were compared between the two groups during the treatment and after the end of the treatment.After 1 month at the end of the radiotherapy,the brain enhanced MRI was reviewed,and the total effective rate (RR),the progression free survival period and the total survival period were compared between the two groups.Results The total effective rate (RR)of the study group was higher than that of the control group,with significant difference (P＜0.05).The median progression free survival of the study group was 3.9 months,which was higher than that of the control group for 2.8 months,and the difference was statistically significant(P＜0.05).The median overall survival of the study group was 6.1 months,which was 5.2 months in the control group,there was no significant difference between the two groups(P＞0.05).In the study group of adverse reactions,most of them were granulocytic,digestive tract reaction and headache and dizziness,all of which were gradeⅠ toⅡ.There was no significant difference in the incidence of adverse reactions between the two groups (P＞0.05).All adverse reactions did not affect radiotherapy after symptomatic treatment.Conclusion whole brain radiotherapy combined with Temozolomide in the treatment of NSCLC brain metastases is highly effective in the near future,and can prolong the progression free survival,the adverse reaction is small,and the patient is well tolerated.

Key words： Non-small cell lung cancer Brain metastases Whole brain radiotherapy Temozolomide

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WAN Lin-lin
	LIU Xiao-hong
	CHEN Kai

Cite this article:

WAN Lin-lin,LIU Xiao-hong,CHEN Kai. Evaluation on the effect of whole brain radiotherapy combined with Temozolomide in the treatment of brain metastases of non-small cell lung cancer[J]. 中国当代医药, 2018, 25(29): 61-63转72.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I29/61

[1]	安辉，朱广迎，余荣，等.非小细胞肺癌伴脑转移放疗疗效分析[J].中华肿瘤杂志，2007，29（7）：545-548.
[2]	Bhangoos S，Linskey M，Kalkanis S.Evidence-based guidelines for the management of brain Metastases[J].Neurosurgery Clin N A，2011，22（1）：97-104.
[3]	Lagerwaard F，Levendag P，Nowak M，et al.Iden-tification of prognostic factors in patients with brain metastases：a review of 1292 patients[J].Int J Radiat Oncol Biol Phys，2015，43（4）：795-803.
[4]	Gaspar L，Scott C，Rotman M，et al.Recursive partitooning analysis （RAP） of prognostic factors in three Radiation Therapy Oncology Group （RTOG）brain metastases trials[J].Int J Radiat Oncol Biol Phys，2015，37（4）：745-751.
[5]	Gamboa S，Vignolle IC，Ferrari C，et al.Whole-brain irradiation with concomitant daily fixed dose temozolomide for brain metastases treatment：a randomised phase Ⅱ trial[J].Radiother Oncol，2012，102（2）：187-191.
[6]	Abrey L，Olson JD，Raizer J，et al.A phase Ⅱ trial of temozolomide for patients with recurrent or progressive brain metastases[J].J Neurooncl，2009，53（3）：259-265.
[7]	Cortot A，Gefini L，Robinet G，et al.Phase Ⅱ trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases：a GLOT-GFPC study[J].Ann Oncol，2014，17（9）：1412-1417.
[8]	Wilhelm I，Molnar J，Fazakas C，et al.Role of the bloodbrain barrier in the formation of brain metastases[J].Int J Mol Sci，2013，14（1）：1383-1411.
[10]	庞华，张君仁，赵丽.替莫唑胺的合成及抗肿瘤活性[J].中国医药工业杂志，2003，34（2）：218-220.
[11]	康勋，李珊，谢铮铮，等.恶性脑胶质瘤同步放化疗中替莫唑胺化疗的不良反应及对策[J].首都医科大学学报，2012，33（5）：589-593.
[12]	覃莉，黄海欣，陈海辉，等.替莫唑胺联合干扰素治疗晚期黑色素瘤的临床研究[J].肿瘤药学，2013，3（3）：196.
[14]	印海林，吴伟莉，金风，等.调强放射治疗联合同步及辅助替莫唑胺化疗治疗脑胶质瘤术后残余病灶的临床研究[J].肿瘤，2015，31（5）：428-430.
[9]	Sperduto PW，Chao ST，Sneed PK，et al.Diagnosis-specific prognostic factors，indexes，and treatment outcomes for patients with newly diagnosed brainmetastases：a multi-institutional analysis of 4，259 patients[J].Int J Radio Biol Phys，2010，77（3）：655-661.
[13]	Vanrljn J，Heimansj J，Vandenberg J，et al.Survival of human glioma cells treated with various combination of temozolomide and x-rays[J].Int J Radiat Oncol Biol Phys，2013，47（3）：779-784.
[15]	Addeo R，De R，Faiola V，et al.Phase 2 trial of temozolomideusing protracted low-dose and whhole-brain radiotheerapy for nonsmall cell lung cancer and breast cancer patients with brain metastases[J].Cancer，2014，113（9）：2524-2531.